Indaptus Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
INDP Nasdaq 2830 indaptusrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants - Jul 1st, 2025 6:14 am
Indaptus Therapeutics Announces Reverse Stock Split - Jun 25th, 2025 5:00 am
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - Jun 13th, 2025 6:00 am
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - Jun 2nd, 2025 6:00 am
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 14th, 2025 6:00 am
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - May 8th, 2025 6:00 am
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - Mar 25th, 2025 6:00 am
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 - Mar 20th, 2025 6:00 am
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - Mar 18th, 2025 6:00 am
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - Mar 13th, 2025 5:30 am
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Mar 12th, 2025 2:15 pm
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - Mar 4th, 2025 6:00 am
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - Feb 25th, 2025 6:00 am
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - Feb 5th, 2025 6:00 am
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Jan 13th, 2025 6:00 am
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - Jan 8th, 2025 6:00 am
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - Nov 22nd, 2024 6:36 am
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 12th, 2024 6:00 am
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - Nov 11th, 2024 6:00 am
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - Nov 7th, 2024 6:00 am